Oncology care is becoming increasingly relevant for healthcare organizations and professionals. Overall cancer rates are increasing due to rising life expectancy and growing populations. In 2030, more than 21 million men and women worldwide could develop cancer – 50% more than in 2012.1 Because of the exponential growth in the number of patients and the related costs, it’s key to identify advances tailored to improve care and patient outcomes.
This dossier explores how liquid biopsies are starting to transform the clinical routine and how to utilize the rapidly growing genomic data. A deeper understanding of molecular heterogeneity and the evolution of tumors, in particular, has opened the door for personalized cancer care. The molecular dynamics of lung cancer, for example, can be tracked using genetic signatures in the blood.2
1International Agency for Research on Cancer, Globocan 2012: http://globocan.iarc.fr/Pages/burden_sel.aspx (accessed 8 May 2017)
2Abbosh C, Birkbak NJ, Wilson GA, et al. (2017) Phylogenetic ctDNA analysis depicts early stage lung cancer evolution. Nature, 26 April 2017. doi: 10.1038/nature22364 (Epub ahead of print)
The statements by Siemens’ customers described herein are based on results that were achieved in the customer's unique setting. Since there is no "typical" hospital and many variables exist (e.g., hospital size, case mix, level of IT adoption) there can be no guarantee that other customers will achieve the same results.